surmount-1 trial tirzepatide weight loss non-diabetic Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 Tirzepatide Was Associated with Improved

During Treatment Your treatment ships straight to your door

Blue Cross Blue Shield of Michigan eliminated Wegovy, Zepbound, and Saxenda for fully insured large groups at renewals that began in January 2025 thousands have already lost coverage

Although gastrointestinal side effects and changes in the brains reward system may occur, they also create an opportunity to reexamine your relationship with food

During clinical trials, participants experienced substantial weight reduction, losing up to 20.9% of their body weight

Stimulating both pathways simultaneously produces a synergistic growth hormone release that is significantly greater than either peptide alone